Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med's Surufatinib Granted Orphan Status in US

publication date: Nov 26, 2019

Hutchison China MediTech (Chi-Med) reported the US FDA has granted Orphan Drug designation to the company's surufatinib as a treatment for pancreatic neuroendocrine tumors (NET). Two weeks ago, China's NMPA accepted Chi-Med's surufatinib NDA for review to treat advanced non-pancreatic NET. Surufatinib, the second novel Chi-Med oncology drug to complete a China Phase III trial, is being tested in multiple solid tumors in China and the US, both as a monotherapy and in combination with immunotherapies. With US orphan drug status, surufatinib will be entitled to seven years of market exclusivity. More details....

Stock Symbols: (AIM/NSDQ: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.